In Reply to ‘Discounting the Efficacy of Sulodexide in Diabetic Nephropathy Is Premature’ and ‘Surrogate Versus Clinical End Points and Venture Capital Companies: The Doubts of a Clinician'

✍ Scribed by Matthew A. Weir; Andrew A. House

• Book ID: 114471135
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 143 KB
• Volume: 60
• Category: Article
• ISSN: 0272-6386
• DOI: 10.1053/j.ajkd.2012.04.015